<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Osteoporosis; Osteoporosis: calcium; Osteoporosis: postmenopausal; Osteoporosis: HRT; Hormone replacement: osteoporosis; Bisphosphonates: osteoporosis; Alendronic acid; Disodium etidronate; Risedronate sodium; Osteoporosis: bisphosphonates; Osteoporosis: calcitriol; Osteoporosis: strontium ranelate; Strontium ranelate; Calcitonin; Osteoporosis: calcitonin; Teriparatide; Osteoporosis: teriparatide; Parathyroid hormone; Osteoporosis: parathyroid hormone; Raloxifene; Osteoporosis: raloxifene; Osteoporosis: corticosteroid-induced" /><meta name="IX" content="Osteoporosis; Osteoporosis: calcium; Osteoporosis: postmenopausal; Osteoporosis: HRT; Hormone replacement: osteoporosis; Bisphosphonates: osteoporosis; Alendronic acid; Disodium etidronate; Risedronate sodium; Osteoporosis: bisphosphonates; Osteoporosis: calcitriol; Osteoporosis: strontium ranelate; Strontium ranelate; Calcitonin; Osteoporosis: calcitonin; Teriparatide; Osteoporosis: teriparatide; Parathyroid hormone; Osteoporosis: parathyroid hormone; Raloxifene; Osteoporosis: raloxifene; Osteoporosis: corticosteroid-induced" /><title>Osteoporosis: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4643-osteoporosis.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4643-osteoporosis.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4643-osteoporosis.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4031-endocrine-system.htm">6 Endocrine system</a> &gt; <a href="PHP4642-drugs-affecting-bone-metabolism.htm">6.6 Drugs affecting bone metabolism</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4642-drugs-affecting-bone-metabolism.htm" title="Previous: 6.6 Drugs affecting bone metabolism">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4645-calcitonin-and-parathyroid-hormone.htm" title="Next: 6.6.1 Calcitonin and parathyroid hormone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Osteoporosis</h1><?highlighter on?><div id="pC" class="jN"><p>Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids (glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack of physical activity, family history of osteoporosis, and early menopause.</p><div class="cI"><p>Those at risk of osteoporosis should maintain an adequate intake of <strong>calcium and vitamin D</strong> and any deficiency should be corrected by increasing dietary intake or taking supplements.</p></div><p>Elderly patients, especially those who are housebound or live in residential or nursing homes, are at increased risk of calcium and vitamin D deficiency and may benefit from supplements (<a title=" Calcium supplements" href="PHP6085-calcium-supplements.htm">section 9.5.1.1</a> and <a title=" Vitamin D" href="PHP6223-vitamin-d.htm">section 9.6.4</a>). Reversible secondary causes of osteoporosis such as hyperthyroidism, hyperparathyroidism, osteomalacia or hypogonadism should be excluded, in both men and women, before treatment for osteoporosis is initiated.</p> <div id="PHP4644"><h2>Postmenopausal osteoporosis</h2><p>The <strong>bisphosphonates</strong> (alendronic acid, disodium etidronate, and risedronate, <a title=" Bisphosphonates" href="PHP4652-bisphosphonates-and-other-drugs-affecting-bone-metabolism.htm">section 6.6.2</a>) are effective for preventing postmenopausal osteoporosis. <strong>Hormone replacement therapy</strong> (HRT <a title=" Oestrogens and HRT" href="PHP4384-oestrogens-and-hrt.htm">section 6.4.1.1</a>) is an option where other therapies are contra-indicated, cannot be tolerated, or if there is a lack of response. The CSM has advised that HRT should <strong>not</strong> be considered first-line therapy for long-term prevention of osteoporosis in women over 50 years of age. HRT is of most benefit for the prophylaxis of postmenopausal osteoporosis if started early in menopause and continued for up to 5 years, but bone loss resumes (possibly at an accelerated rate) on stopping HRT. <strong>Calcitonin </strong>(<a title=" Calcitonin" href="PHP4645-calcitonin-and-parathyroid-hormone.htm">section 6.6.1</a>) may be considered for those at high risk of osteoporosis for whom a bisphosphonate is unsuitable. Women of Afro-Caribbean origin appear to be less susceptible to osteoporosis than those who are white or of Asian origin.</p><p>Postmenopausal osteoporosis may be <em>treated</em> with a <strong>bisphosphonate</strong> (<a title=" Bisphosphonates" href="PHP4652-bisphosphonates-and-other-drugs-affecting-bone-metabolism.htm">section 6.6.2</a>). The bisphosphonates (such as alendronate, etidronate, and risedronate) decrease the risk of vertebral fracture; alendronate and risedronate have also been shown to reduce non-vertebral fractures. If bisphosphonates are unsuitable <strong>calcitriol</strong> (<a title=" Vitamin D" href="PHP6223-vitamin-d.htm">section 9.6.4</a>), <strong>calcitonin</strong> or <strong>strontium ranelate</strong> (<a title="BNF:monograph-family: Strontium ranelate" href="PHP4694-strontium-ranelate.htm">section 6.6.2</a>) may be considered. Calcitonin [unlicensed indication] may also be useful for pain relief for up to 3 months after a vertebral fracture if other analgesics are ineffective. <strong>Parathyroid hormone</strong>, and <strong>teriparatide</strong> (<a title="sub-section: Calcitonin" href="PHP4645-calcitonin-and-parathyroid-hormone.htm">section 6.6.1</a>) have been introduced for the treatment of postmenopausal osteoporosis.</p><p><strong>Raloxifene</strong> (<a title=" Oestrogens and HRT" href="PHP4384-oestrogens-and-hrt.htm">section 6.4.1.1</a>) is licensed for the <em>prophylaxis</em> and <em>treatment</em> of vertebral fractures in postmenopausal women.</p></div> <div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</h3><p><strong>Alendronate</strong> is recommended as a treatment option for the primary prevention of osteoporotic fractures in the following susceptible postmenopausal women: </p><ul><li><p>Women over 70 years who have an independent risk factor for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis) <em>or</em> an indicator of low bone mineral density (body mass index under 22 kg/m<sup>2</sup>, ankylosing spondylitis, Crohn's disease, prolonged immobility, untreated premature menopause, or rheumatoid arthritis) <strong>and</strong> confirmed osteoporosis</p> </li><li><p>Women aged 65–69 years who have an independent risk factor for fracture <strong>and</strong> confirmed osteoporosis</p> </li><li><p>Women under 65 years who have an independent risk factor for fracture <strong>and</strong> at least one additional indicator of low bone mineral density <strong>and</strong> confirmed osteoporosis</p> </li></ul><p><strong>Risedronate</strong> or <strong>etidronate</strong> are recommended as alternatives for women:</p><ul><li><p>in whom alendronate is contra-indicated or not tolerated <strong>and</strong></p> </li><li><p>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance<cite><a href="PHP4643-osteoporosis.htm#PHP10702" class="tooltip PHP10702">(1)</a></cite></p> </li></ul><p><strong>Strontium ranelate</strong> is recommended as an alternative for women:</p><ul><li><p>in whom alendronate and either risedronate or editronate are contra-indicated or not tolerated <strong>and</strong></p> </li><li><p>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance<cite><a href="PHP4643-osteoporosis.htm#PHP10702" class="tooltip PHP10702">(1)</a></cite></p> </li></ul><p><strong>Raloxifene</strong> is <strong>not</strong> recommended as a treatment option in postmenopausal women for primary prevention of osteoporotic fractures.</p></div> <div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</h3><p>This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.</p><p><strong>Alendronate</strong> is recommended as a treatment option for the secondary prevention of osteoporotic fractures in susceptible postmenupausal women.</p><p><strong>Risedronate</strong> or <strong>etidronate</strong> are recommended as alternatives for women:</p><ul><li><p>in whom alendronate is contra-indicated or not tolerated <strong>and</strong> </p> </li><li><p>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance<cite><a href="PHP4643-osteoporosis.htm#PHP10703" class="tooltip PHP10703">(2)</a></cite></p> </li></ul><p><strong>Strontium ranelate</strong> or <strong>raloxifene</strong> are recommended as alternatives for women:</p><ul><li><p>in whom alendronate and either risedronate or editronate are contra-indicated or not tolerated <strong>and</strong></p> </li><li><p>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance<cite><a href="PHP4643-osteoporosis.htm#PHP10703" class="tooltip PHP10703">(2)</a></cite></p> </li></ul><p><strong>Teriparatide</strong> is recommended as an alternative for women:</p><ul><li><p>in whom alendronate and either risedronate or editronate, <em>or</em> strontium ranelate are contra-indicated or not tolerated, <strong>or</strong> where treatment with alendronate, risedronate or editronate has been unsatisfactory (indicated by another fragility fracture and a decline in bone mineral density despite treatment for 1 year) <strong>and</strong> </p> </li><li><p>who comply with particular combinations of bone mineral density measurement, age, and number of fractures, as indicated in the full NICE guidance<cite><a href="PHP4643-osteoporosis.htm#PHP10703" class="tooltip PHP10703">(2)</a></cite></p> </li></ul></div> <div><h2>Corticosteroid-induced osteoporosis</h2><p>To reduce the risk of osteoporosis doses of oral corticosteroids should be as low as possible and courses of treatment as short as possible. The risk of osteoporosis may be related to cumulative dose of corticosteroids; even intermittent courses can therefore increase the risk. The greatest rate of bone loss occurs during the first 6–12 months of corticosteroid use and so early steps to prevent the development of osteoporosis are important. Long-term use of high-dose inhaled corticosteroids may also contribute to corticosteroid-induced osteoporosis (<a title="section: Corticosteroids" href="PHP1843-corticosteroids.htm">section 3.2</a>).</p><p>Patients taking (or who are likely to take) an oral corticosteroid for 3 months or longer should be assessed and where necessary given prophylactic treatment; those aged over 65 years are at greater risk. Patients taking oral corticosteroids who have sustained a low-trauma fracture should receive treatment for osteoporosis. The therapeutic options for <em>prophylaxis</em> and <em>treatment</em> of corticosteroid-induced osteoporosis are the same:</p><ul><li><p>a bisphosphonate (<a title="BNF:monograph-family: Bisphosphonates" href="PHP4653-bisphosphonates.htm">section 6.6.2</a>);</p> </li><li><p>calcitriol [unlicensed indication] (<a title="BNF:monograph: CALCITRIOL" href="PHP6240-calcitriol.htm">section 9.6.4</a>);</p> </li><li><p>hormone replacement (HRT in women (<a title="topic: Hormone replacement therapy" href="PHP4405-hormone-replacement-therapy.htm">section 6.4.1</a>), testosterone in men [unlicensed indication] (<a title="monograph: TESTOSTERONE AND ESTERS" href="PHP4512-testosterone-and-esters.htm">section 6.4.2</a>)).</p> </li></ul></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4642-drugs-affecting-bone-metabolism.htm">Previous: 6.6 Drugs affecting bone metabolism</a> | <a class="top" href="PHP4643-osteoporosis.htm#">Top</a> | <a accesskey="]" href="PHP4645-calcitonin-and-parathyroid-hormone.htm">Next: 6.6.1 Calcitonin and parathyroid hormone</a> ►</div><ol class="cC"><li class="footnote" id="PHP10702"><p>Available at <a href="http://www.nice.org.uk/TA160">www.nice.org.uk/TA160</a></p></li><li class="footnote" id="PHP10703"><p>Available at <a href="http://www.nice.org.uk/TA161">www.nice.org.uk/TA161</a></p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>